Next Article in Journal
Role of Cytokine Signaling during Nervous System Development
Next Article in Special Issue
Chlamydia pneumoniae Infection in Atherosclerotic Lesion Development through Oxidative Stress: A Brief Overview
Previous Article in Journal
Sarcosine as a Potential Prostate Cancer Biomarker—A Review
Previous Article in Special Issue
Potential Mechanisms Linking Atherosclerosis and Increased Cardiovascular Risk in COPD: Focus On Sirtuins
Article Menu

Export Article

Open AccessReview
Int. J. Mol. Sci. 2013, 14(7), 13909-13930; doi:10.3390/ijms140713909

The Efficacy of Edaravone (Radicut), a Free Radical Scavenger, for Cardiovascular Disease

1
Department of Pharmacology, Faculty of Dentistry, Mahidol University, 6 Yothe Road, Rajthevee, Bangkok 10400, Thailand
2
Division of Brain Science, Department of Physiology, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan
3
Department of Neurosurgery, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan
*
Author to whom correspondence should be addressed.
Received: 23 May 2013 / Revised: 19 June 2013 / Accepted: 21 June 2013 / Published: 4 July 2013
(This article belongs to the Special Issue Oxidative Stress in Cardiovascular Disease)
View Full-Text   |   Download PDF [261 KB, uploaded 19 June 2014]

Abstract

Edaravone was originally developed as a potent free radical scavenger, and has been widely used to treat acute ischemic stroke in Japan since 2001. Free radicals play an important role in the pathogenesis of a variety of diseases, such as cardiovascular diseases and stroke. Therefore, free radicals may be targets for therapeutic intervention in these diseases. Edaravone shows protective effects on ischemic insults and inflammation in the heart, vessel, and brain in experimental studies. As well as scavenging free radicals, edaravone has anti-apoptotic, anti-necrotic, and anti-cytokine effects in cardiovascular diseases and stroke. Edaravone has preventive effects on myocardial injury following ischemia and reperfusion in patients with acute myocardial infarction. Edaravone may represent a new therapeutic intervention for endothelial dysfunction in the setting of atherosclerosis, heart failure, diabetes, or hypertension, because these diseases result from oxidative stress and/or cytokine-induced apoptosis. This review evaluates the potential of edaravone for treatment of cardiovascular disease, and covers clinical and experimental studies conducted between 1984 and 2013. We propose that edaravone, which scavenges free radicals, may offer a novel option for treatment of cardiovascular diseases. However, additional clinical studies are necessary to verify the efficacy of edaravone.
Keywords: edaravone; cardiovascular disease; free radical scavenger edaravone; cardiovascular disease; free radical scavenger
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Kikuchi, K.; Tancharoen, S.; Takeshige, N.; Yoshitomi, M.; Morioka, M.; Murai, Y.; Tanaka, E. The Efficacy of Edaravone (Radicut), a Free Radical Scavenger, for Cardiovascular Disease. Int. J. Mol. Sci. 2013, 14, 13909-13930.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top